BNTC

Benitec Biopharma Inc · NASDAQ

Sector Health Technology
Industry Biotechnology
Website benitec.com
Employees(FY) 18
ISIN US08205P2092

Performance

-6.96%

-10.62%

+5.57%

+27.58%

+202.17%

YTD

+187.48%

Profile

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Advanced Technical Analysis

Technical Analysis of BNTC 2024-12-02

The stock indicators reflect a bearish sentiment overall, with the Moving Average Score at 36, Oscillators Score at 40, and a Technical Score of 38, indicating a lack of strong bullish momentum and suggesting caution for potential investors. The scores collectively point to a market environment that may be struggling to gain upward traction.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of BNTC

Stock Rank

Recent News & Updates

2024-11-25 18:00
Benitec Biopharma to Participate in Upcoming Investor Conferences in December(Globenewswire)
2024-11-14 03:30
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update(Globenewswire)
2024-11-03 19:00
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference(Globenewswire)
2024-10-25 05:01
Janus Henderson Group PLC Expands Investment in Benitec Biopharma Inc(Yahoo Finance)
2024-10-13 18:00
Benitec Biopharma Announces Updated Investor Webcast Information(Globenewswire)
2024-10-11 18:30
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society(Globenewswire)
2024-09-30 09:03
Suvretta Capital Management's Strategic Acquisition in Benitec Biopharma Inc(Yahoo Finance)
2024-09-26 04:30
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update(Globenewswire)
2024-09-17 20:00
Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society(Globenewswire)
2024-09-16 20:00
Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar(Globenewswire)
2024-07-14 18:00
Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study(Globenewswire)
2024-06-30 19:00
Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors(Globenewswire)
2024-05-13 02:53
BNTC Stock Earnings: Benitec Biopharma Misses EPS for Q3 2024(Investorplace)
2024-05-12 20:15
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update(Globenewswire)
2024-04-30 20:00
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference(Globenewswire)
2024-04-17 19:30
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study(Globenewswire)
2024-04-17 19:00
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million(Globenewswire)
2024-04-08 20:00
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024(Globenewswire)
2024-03-23 19:55
11 Best ASX Stocks To Buy Now(Insidermonkey)
2024-02-12 19:00
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update(Globenewswire)
2023-11-29 18:00
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy(Globenewswire)
2023-11-16 19:00
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference(Globenewswire)
2023-11-12 19:00
Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update(Globenewswire)
2023-09-20 20:00
Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update(Yahoo Finance)
2023-08-21 09:02
Citadel Advisors LLC Acquires New Stake in Benitec Biopharma Inc(Yahoo Finance)
2023-08-18 09:02
JANUS HENDERSON GROUP PLC Acquires New Stake in Benitec Biopharma Inc(Yahoo Finance)
2023-08-11 01:00
Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering(Yahoo Finance)
2023-08-08 10:30
Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering(Yahoo Finance)
2023-07-25 01:00
Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023(Yahoo Finance)
2023-06-25 20:00
Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy(Yahoo Finance)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.